Botulinum toxin (BTX) blocks the release of acetylcholine at the neuromuscular junction leading to a state of muscle paralysis that may last for months. It is considered as the most potent biological neurotoxin, causing high morbidity and death. This fact led to misconception of the toxin in the past. However, over the past decade a complete renewal of its image took place and nowadays botulinum toxin is widely known as a therapeutic agent with multiple indications, specially after being widely marketed to the public as an antiwrinkle tool for facial cosmetics. Nevertheless, it has revolutionized the treatment of many chronic neurological disorders with marked improvement in the quality of life and disability due to spasticity, hemifacial spasm, spasmodic dysphonia, hyperhidrosis, as well as many dystonic conditions. In Brazil, BTX was licensed for the treatment of various movement disorders in 1992, and has been successfully used in the management of blepharospasm (BP). Before the advent of this treatment, BP was considered a disabling condition with poor response to oral medications. Because it is a chronic disease, it is important to ensure that the treatment strategies are both safe and effective after long periods of maintenance, and that the patients report satisfaction with the lengthy treatment.

Since there are no previous reports regarding the use of BTX in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine from 1993 to 2003. A total of 379 treatments with BTX were administered to 30 patients with blepharospasm. Sixty six per cent of the subjects had used oral medication for dystonia and only 15% of them reported satisfactory response to this treatment. Ninety three per cent of the patients showed significant improvement after the first BTX injection. There was no decrement in response when compared the first and the last injection recorded. Adverse effects, mostly minor, developed at least once in 53% of patients. Six patients (20%) discontinued the treatment but there was no case of secondary resistance.

**ABSTRACT** - To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine from 1993 to 2003. A total of 379 treatments with BTX were administered to 30 patients with blepharospasm. Sixty six per cent of the subjects had used oral medication for dystonia and only 15% of them reported satisfactory response to this treatment. Ninety three per cent of the patients showed significant improvement after the first BTX injection. There was no decrement in response when compared the first and the last injection recorded. Adverse effects, mostly minor, developed at least once in 53% of patients. Six patients (20%) discontinued the treatment but there was no case of secondary resistance.

**KEY WORDS:** botulinum toxin, blepharospasm, dystonia.
the long-term effects of BTX in the treatment of blepharoespasm in our country, the aim of this article is to describe our findings after 10-year experience.

**METHOD**

A retrospective analysis was conducted from data of 30 patients, who received botulinum neurotoxin type A (Botox-Allergan) at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine (HC-USP) over the past 10 years (1993 to 2003), to describe the long-term efficacy and side effects of the treatment of blepharospasm with BTX. The past medical history of the patients regarding comorbidities and previous use of oral medication or surgical procedures were reported.

The scheme of injection was performed according to a 10 symmetrical points modified from an original scheme proposed by Consky (Fig 1). Sites of injection were sometimes changed depending on the effects of the toxin achieved after each application, either to enhance its efficacy or to decrease collateral effects. The dose at the first application was usually 5 units per point. In the following injections the dose was calculated based on the therapeutic response and tolerance.

The efficacy of the application was evaluated by the

![Fig 1. Injection points scheme for the treatment of blepharospasm used in the HC - FMUSP.](image)

**Fig 1.** Injection points scheme for the treatment of blepharospasm used in the HC - FMUSP.

![Fig 2. Response to BTX applications. The data is displayed in bars showing the results in different moments of the follow-up. Bars: A) Current response of the patients who achieved more than 10 years of follow-up. B) Last registered application response of all patients. C) Current response of all the patients still on follow-up. D) First application response of all patients. Statistical analysis was performed comparing bars B, C and D to observe changes in response over time. There was no significant difference between the response to the first and the last application registered for each patient (bars D and B; p=0.7632 according to a paired Student t test) or between the response to the first application for all patients and the current average response in patients who are still on follow-up (bars D and C; p=0.2365 according to a non-paired Student t test).](image)
RESULTS

A total of 379 treatments with multiple site injections of BTX were administered to 30 patients with BP in a 10-year period. The mean age of the patients at the onset of the symptoms was 53.1 years (SD 9.87) and the mean age at the begging of the treatment was 58 years; 80% of them were female. Twenty two per cent of the patients met criteria for Meige syndrome (dystonic hyperactivity affecting not only the periorcular muscles but also muscles of the lower part of the face, such as perioral, jaw and platismal muscles), and 23% of them had dystonia affecting other cranial or cervical regions, mainly cervical dystonia (66% of these patients). Previously to the BTX treatment 63% of the patients had used oral medication for dystonia (73% used biperiden, 63% used some benzodiazepine, 21% used baclofen; other drugs were used by a minority of patients). Only 15% of these patients reported good response with oral drugs.

Ninety three per cent of the patients showed significant improvement with the first BTX injection. The average improvement at the first application for those who responded was 69%. The average response to the injections for those who took oral medications previously to BTX treatment was 74% and for those who did not use medications 62%; however, this difference was analyzed using the Student t test and revealed to be not significant (p=0.5272). The mean time of follow-up was 4.95 years, average of 12.63 applications per patient, and 60.93 units per application (SD=19.38). The mean duration of improvement was 2.64 months. The average benefit reported at the last application of all patients still on follow-up was 71.96%. Five patients achieved 10 years of follow-up, in those the mean response for the last application was more than 10% higher than the response to the first application, but this difference was not analyzed due to the small number of patients. In general, there was no decrement in response for the patients during the follow-up period as can be seen in Fig 2.

Adverse effects, mostly minor, developed at least once during the treatment in 53% of patients, the most frequent was ptosis (81%) followed by diplopia (12.5%). Six patients (20%) discontinued treatment for diverse reasons. Of these, 3 presented primary resistance. Two of them had eye-opening apraxia confirmed by eletroneuromyography. One patient had only 1 application with no result, and abandoned treatment. There was no case of secondary resistance. One patient who did not responded adequately to BTX injections in the beginning of her treatment was referred to a neurectomy and after this procedure presented satisfactory response to BTX applications with an average response rate of 60%.

DISCUSSION

Results evidenced that BTX injections offered very good response rate with sustained effects while the use of oral medication was highly unsatisfactory and did not interfere with the response to the BTX treatment. In our opinion, a trial of oral medication (also suggested in literature) is recommended since in public services the waiting list for the BTX treatment is usually very long.

In the literature some authors published similar results of long-term treatments for different neurological movement disorders, hyperhidrosis, as well as other disease. About blepharospasm, there were some cases included in large treatment series for diverse neurological disorders and their results resembled the ones observed in the present study. Concerns about long-term use of BTX in the muscle can be refuted since Borodic showed no irreversible muscle atrophy in histological analysis of orbicularis oculi muscles of 11 patients who had received botulinum toxin over 3.5 years.

The apparent high rate of adverse effects (53%) can be explained in this analysis since collateral effects were scored if they manifested at least once. This contrasts other data from the literature which consider the proportion of injections related to the
collateral effect among the total number of injections in a short period. This tends to reduce the percentage of reported adverse effects since they can be avoided with changes in the procedure, then decreasing the rate of collateral effects in future injections. Nevertheless, collateral effects were well tolerated in our series and were not related to abandonment of treatment. Ptosis is related to the action of BTX on levator palpebrae muscle, while diplopia is more uncommon and is usually related to the effect of BTX in lateral rectus muscle\textsuperscript{18}, either for excessive diffusion of the toxin or misplacement of the application points in the superior palpebrae. Both can be avoided by correction of the injection site, decrease in the dosage or dilution. Ptosis can be prevented avoiding the central portion of the eyelid and diplopia by placing the needle more laterally to the injection site. Eye-opening apraxia, although fairy uncommon, has been previously related to BTX resistance\textsuperscript{19}, and in our series, the patients drop out the treatment. Although secondary resistance to blepharospasm treatment with botulinum toxin has been already reported in the literature\textsuperscript{20}, none of our patients had this evolution.

Overall, the results showed that BTX was a safe and effective treatment for blepharospasm and most of the side effects were well tolerated. Levels of response in the present study were comparable to those achieved in general literature. In those series, most of the patients referred subjective degree of improvement between 70\% and 90\%\textsuperscript{20}. Discontinuation for diverse reasons was also low after 10 years of follow-up. In our series, efficacy was maintained after long periods of treatment with high degree of patient satisfaction.

Acknowledgement - For his help in the analysis of data from the patients we thank Dr. Alexandre Maria Santos from the Department of Neurology, Division of Neurosurgery, Hospital das Clínicas, University of São Paulo School of Medicine.

REFERENCES